Browsing by Author "Tanno, Federico"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    A Latin American survey on demographic aspects of hospitalized, decompensated cirrhotic patients and the resources for their management
    (2020) Vorobioff, Julio D.; Contreras, Fernando; Tanno, Federico; Hernandez, Lucia; Bessone, Fernando; Colombato, Luis; Adi, Jose; Fassio, Eduardo; Felgueres, Mirta; Fernandez, Guillermo; Gaite, Luis; Gibelli, Diana; Gomez Darrichon, Hernan; Lafage, Matias; Lombardo, Daniel; Lopez, Susana; Mateo, Alejandro; Mendizabal, Manuel; Pecoraro, Julieta; Ruf, Andres; Ruiz, Pablo; Severini, Javier; Stieben, Teodoro; Sixto, Marcela; Zarate, Fabian; de la Barra Barraza, Sergio; Donoso Sierra, Irene; Rivas Pacheco, Violeta; Roblero, Juan P.; Rojas, Juan O.; Ruiz Gonzalez, Patricio; San Martin Rodriguez, Diego; Sierralta, Armando; Urzua Manchego, Alvaro; Valdes, Eliana; Yaquich, Pamela; Wolff, Rodrigo; Beltran Valdivia, Flor; Gallegos, Roxana C.; Galloso, Rocio; Marcelo, Julio S.; Montes, Pedro; Tenorio, Laura; Veramendi, Isabel; Alava, Elizabeth; Armijos, Ximena; Benalcazar, Gonzalo; Carrera, Enrique; Pazmino, Galo F.; Marriott Diaz, Eduardo; Garassini, Miguel; Marrero, Rosalia P.; Infante, Mirta; Paez Suarez, Dayron; Gutierrez, Jose C.; Villadoniga Reyes, Carmen M.; Serrano, Yoel M.; Hernandez Hernandez, Rivardo; Martinez Martinez, Orelvis; Perez Gonzalez, Teresita; Andara, Maria T.; Sanchez Hernandez, Marco; Gerona, Solange; Garcia, Ivan; de la Tijera, Fatima; Pessoa Lopez, Edmundo; Torres, Kenia; Garzon, Martin
    Introduction & objectives: Liver cirrhosis is a major cause of mortality worldwide. Adequate diagnosis and treatment of decompensating events requires of both medical skills and updated technical resources. The objectives of this study were to search the demographic profile of hospitalized cirrhotic patients in a group of Latin American hospitals and the availability of expertise/facilities for the diagnosis and therapy of decompensation episodes.
  • Thumbnail Image
    Item
    Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort
    (2020) Ridruejo, Ezequiel; Piñero, Federico; Mendizabal, Manuel; Cheinquer, Hugo; Soza, Alejandro; Herz Wolff, Fernando; Anders, Margarita; Reggiardo, Virginia; Ameigeiras, Beatriz; Palazzo, Ana; Alonso, Cristina; Schinoni, María Isabel; Videla Zuain, María Grazia; Tanno, Federico; Figueroa, Sebastián; Santos, Luisa; Peralta, Mirta; Vistarini, Cecilia; Adrover, Raúl; Fernández, Nora
  • No Thumbnail Available
    Item
    Nitrofurantoin-induced liver injury: long-term follow-up in two prospective DILI registries
    (2023) Bessone, Fernando; Ferrari, Antonella; Hernandez, Nelia; Mendizabal, Manuel; Ridruejo, Ezequiel; Zerega, Alina; Tanno, Federico; Reggiardo, Maria Virginia; Vorobioff, Julio; Tanno, Hugo; Arrese, Marco; Nunes, Vinicius; Tagle, Martin; Medina-Caliz, Inmaculada; Robles-Diaz, Mercedes; Niu, Hao; Alvarez-Alvarez, Ismael; Stephens, Camilla; Lucena, M. Isabel; Andrade, Raul J.
    Nitrofurantoin is a synthetic antibiotic that is recommended as first-choice treatment for uncomplicated urinary tract infections. The prescription of this drug has increased dramatically, especially in Latin American countries. We described the demographics, clinical characteristics, biochemical features, and outcome of nitrofurantoin-induced liver injury. We analyzed 23 cases from the Latin American DILI Network (LATINDILI) and the Spanish DILI Registry. Causality was assessed with the RUCAM and RECAM scale. Of the 23 DILI cases included in our series, 96% patients were women, and the mean age of the whole cohort was 61 years. The median time of drug exposure was 175 days (interquartile range [IQR] 96-760), with 11 patients who were prescribed nitrofurantoin for more than six months. Hepatocellular damage was the most frequent pattern of liver injury (83%), and nearly half of the patients had an asymptomatic presentation (52%). Neither death nor liver transplantation was documented in this series. Overall, 65% of the patients (n = 15) presented with positive autoantibody titres. The median time to resolution was 81 days (IQR 57-141), and 15 patients (83%) recovered within six months. Five patients (22%) developed nitrofurantoin-induced autoimmune-like hepatitis (NI-AILH), of whom two were characterized by a persistent increase in transaminases that required immunosuppressive treatment to achieve normalization of liver enzymes. Clinicians who prescribe nitrofurantoin should be aware that patients who had taken nitrofurantoin for a long term may be at risk of developing nitrofurantoin-induced autoimmune-like hepatitis.
  • No Thumbnail Available
    Item
    Serious liver injury induced by Nimesulide: an international collaborative study
    (2021) Bessone, Fernando; Hernandez, Nelia; Mendizabal, Manuel; Ridruejo, Ezequiel; Gualano, Gisela; Fassio, Eduardo; Peralta, Mirta; Fainboim, Hugo; Anders, Margarita; Tanno, Hugo; Tanno, Federico; Parana, Raymundo; Medina-Caliz, Inmaculada; Robles-Diaz, Mercedes; Alvarez-Alvarez, Ismael; Niu, Hao; Stephens, Camilla; Colombato, Luis; Arrese, Marco; Reggiardo, M. Virginia; Ono, Suzane Kioko; Carrilho, Flair; Lucena, M. Isabel; Andrade, Raul J.
    Nimesulide is a non-steroidal anti-inflammatory drug still marketed in many countries. We aim to analyze the clinical phenotype, outcome, and histological features of nimesulide-induced liver injury (nimesulide-DILI). We analyzed 57 cases recruited from the Spanish and Latin American DILI registries. Causality was assessed by the RUCAM scale. Mean age of the whole case series was 59 years (86% women) with a median time to onset of 40 days. A total of 46 patients (81%) were jaundiced. Nimesulide-DILI pattern was hepatocellular in 38 (67%), mixed in 12 (21%), and cholestatic in 7 (12%) cases. Transaminases were elevated with a mean of nearly 20-fold the upper limit of normality (ULN), while alkaline phosphatase showed a twofold mean elevation above ULN. Total bilirubin showed a mean elevation of 13-fold the ULN. Liver histology was obtained in 14 cases (25%), most of them with a hepatocellular pattern. Median time to recovery was 60 days. Overall, 12 patients (21%) developed acute liver failure (ALF), five (8.8%) died, three underwent liver transplantation (5.3%), and the remaining four resolved. Latency was <= 15 days in 12 patients (21%) and one patient developed ALF within 7 days from treatment initiation. Increased total bilirubin and aspartate transaminase levels were independently associated with the development of ALF. In summary, nimesulide-DILI affects mainly women and presents typically with a hepatocellular pattern. It is associated with ALF and death in a high proportion of patients. Shorter (<= 15 days) duration of therapy does not prevent serious nimesulide hepatotoxicity, making its risk/benefit ratio clearly unfavorable.
  • Thumbnail Image
    Item
    Treatment with direct‐acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma
    (2019) Piñero, Federico; Mendizabal, Manuel; Ridruejo, Ezequiel; Herz Wolff, Fernando; Ameigeiras, Beatriz; Anders, Margarita; Schinoni, María Isabel; Reggiardo, María Virginia; Palazzo, Ana; Soza, Alejandro; Videla, María; Alonso, Cristina; Santos, Luisa; Varón, Adriana; Figueroa, Sebastián; Vistarini, Cecilia; Adrover, Raúl; Fernández, Nora; Perez, Daniela; Tanno, Federico; Hernández, Nelia; Sixto, Marcela; Borzi, Silvia; Bruno, Andres; Cocozzella, Daniel; Descalzi, Valeria; Estepo, Claudio; Zerega, Alina; Araujo, Alexandre de; Cheinquer, Hugo; Silva, Marcelo; LALREAN